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Abstract
Magnocellular neuroendocrine cells of the supraoptic nucleus (SON) release the peptides oxytocin (OT) and
vasopressin (VP) from their dendrites and terminals. In addition to peptide-containing large dense-core
vesicles, axon terminals from these cells contain clear microvesicles that have been shown to contain
glutamate. Using multilabelling confocal microscopy, we investigated the presence of vesicular glutamate
transporters (VGLUTs) in astrocytes as well as VP and OT neurones of the SON. Simultaneous probing of the
SON with antibodies against VGLUT isoforms 1–3, OT, VP and glial ﬁbrillary acidic protein (GFAP) revealed
the presence of VGLUT-2 in somata and dendrites of SON neurones. Immunoreactivity (-ir) for VGLUT-3 was
also detected in both OT and VP neurones as well as in GFAP-ir astrocytes and other cells of the ventral glial
lamina. Colocalisation of VGLUT-2 and VGLUT-3 in individual SON neurones was also examined and
VGLUT-ir with both antibodies could be detected in both types of SON neurones. Although VGLUT-1-ir was
strong lateral to the SON, only sparse labelling was apparent within the nucleus, and no colocalisation with
either SON neurones or astrocytes was observed. The SON or the SON plus its surrounding perinuclear zone
was probed using the reverse transcriptase-polymerase chain reaction and the presence of mRNA for all
three VGLUT isoforms was detected. These results suggest that similar arrangements of transmitters exist in
SON neuronal dendrites and their neurohypophysial terminals and that magnocellular neuroendocrine
somata and dendrites may be capable of glutamatergic transmission.
The supraoptic nucleus (SON) forms a major part of the
magnocellular hypothalamic–neurohypophysial neuroendo-
crine system. Individual SON neurones primarily synthesise
either oxytocin (OT) or vasopressin (VP), which are peptide
hormones with well-established roles in water balance,
parturition and lactation. Stored in dense-core vesicles
(DCVs), OT and VP are released from magnocellular neurone
terminals in the pituitary neural lobe (NL) and from dendrites
in the SON. Depending upon the stimulus, the peptide
hormones are released from dendrites, terminals or both (1).
Several neurotransmitters inﬂuence this release via activation
of receptors found both in the SON and NL (2).
In addition to containing DCVs, electron microscopy of the
NL has shown that terminals from magnocellular neurones
contain clear microvesicles (MVs). These MVs show glutam-
ate immunoreactivity (-ir) and appear clustered for release (3).
Additionally, the neural lobe has been found to be immuno-
reactive for VGLUT-2 (4). The coexistence of glutamate-ir
MVs with DCVs in the NL suggests that glutamatergic
vesicles might also coexist with the well-documented DCVs in
the magnocellular somata and dendrites. Exocytotic release of
neuropeptides from SON somata and dendrites, ﬁrst shown
by Pow and Morris (5), accounts for earlier ﬁndings descri-
bing the presence of OT and VP in the hypothalamus, and
their functions in autocrine and retrograde signalling (6).
However, anatomical studies addressing the possibility of
somatodendritic glutamate release are lacking.
Vesicular glutamate transporters (VGLUTs) account for
all of the known glutamatergic transmission in the mamma-
lian brain (7). Currently, three isoforms of VGLUTs are
known to exist. These have been found in both neurones and
astrocytes, with VGLUT-3 located in serotonergic, choliner-
gic, dopaminergic and even GABAergic neurones (8, 9). A
number of studies (4, 10–12) have demonstrated the presence
of VGLUT-2-ir and/or mRNA in the magnocellular neuro-
endocrine system. This is not surprising because the SON is
the destination of myriad glutamate aﬀerents (13). Further-
more, the existence of VGLUTs mRNA has long been known
in various types of synaptic terminals and protoplasmic
astrocytes (which are especially plentiful in the ventral SON)
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of positive magnocellular-neurone and glial identiﬁers, the
precise location of the VGLUT-2-ir and mRNA remains
unclear. This is the ﬁrst study to speciﬁcally address the
presence of VGLUT-3 immunoreactivity in the magnocellular
system and to build upon earlier observations by investigating
the presence of diﬀerent VGLUT isoforms in clearly identi-
ﬁed SON neurones and astrocytes.
Earlier ultrastructural analysis of postembedding glutam-
ate immunocytochemistry revealed microvesicles in the NL
stain for glutamate (3). Additionally, both magnocellular
somata and dendrites are immunoreactive with glutamate
antibodies at the light and electron microscopic level (15).
However, the amino acid glutamate is present in all cells,
functioning in metabolism and incorporated into proteins.
Whether or not it is also used as a regulated signalling
molecule depends upon whether the cell contains machinery
for controlled release of the transmitter. To explore the
possibility of glutamate release from neurones and astrocytes
of the SON, we studied the presence of the three known
VGLUTs and their mRNA, which function in the storage and
concentration of glutamate into synaptic vesicles.
Materials and methods
Immunocytochemistry
Adult male rats (aged 50–80 days) were deeply anaesthetised with sodium
pentobarbital (100 mg/kg) and transcardially perfused with 4% paraformal-
dehyde in 0.1 M phosphate-buffered saline (PBS). Coronal sections (50–60 lm
thick) were cut on a vibratome, treated with 0.3% Triton X-100 in PBS for
30 min and subsequently immunoprocessed (for all antibody identiﬁcation,
see Table 1). Brain sections were incubated with antibodies for either 3 h at
room temperature or overnight at 4  C. All secondary antibodies were made
in donkey and were conjugated to AMCA, FITC (Jackson Laboratories, Bar
Harbor, ME, USA) or the Alexa Flour  350, 488, 546, 555, or 647 (Molecular
Probes, Eugene, OR, USA). A 5-min histochemical treatment with Hoechst
(Sigma, St Louis, MO, USA; 1 : 1000, 1 mg/ml) was also used in several
experiments to stain nuclei. Hoechst, which produces a blue ﬂuorescence in
response to ultraviolet (UV) excitation, is depicted in grey in the confocal
micrographs.
Confocal microscopy
An upright Leica SP2 UV-equipped laser-scanning confocal microscope
(Leica, Heidelberg, Germany) was used in sequential scanning mode with
nonoverlapping photomultiplier tube settings for acquiring all images. All
data were collected with a pinhole set to 1 airy unit corresponding to Z-optical
sections <300 nm. Z-series were collected with a depth difference of
<0.5 lm between successive Z sections.
Cell cultures
We prepared enriched astrocytic cultures using a modiﬁcation (16) of the
originally described shaking procedure (17). Brieﬂy, visual cortices isolated
from 0- to 2-day-old Sprague-Dawley rats were enzymatically treated (papain,
20 IU/ml; 1 h at 36.8  C). After mechanical dispersion, cells were initially
plated into tissue culture ﬂasks (25 cm
2) and maintained at 36.8  Ci na
humidiﬁed 5% CO2 95% air atmosphere in a complete culture medium that
consisted of a-MEM (without phenol red; GibcoTM, Invitrogen Corp.,
Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (HyClone,
Logan, UT, USA), L-glutamine (2 mM; Invitrogen Corp.), D-glucose (20 mM;
Sigma-Aldrich, St Louis, MO, USA), sodium pyruvate (1 mM; Invitrogen
Corp.), penicillin (100 IU/ml), streptomycin (100 lg/ml), and sodium bicar-
bonate (14 mM; Invitrogen Corp.) (pH ¼ 7.4). After 6–24 days in culture, the
cells were shaken twice (260 r.p.m. at 36.8  C), ﬁrst for 1.5–2 h, and then,
after exchange of complete medium, again for 18–20 h. At that time, the
remaining attached cells were detached from ﬂasks using a cell scraper and
used in preparation of subcellular fractions for Western blotting experiments.
The purity (> 99%) of astrocytic culture was conﬁrmed by anti-glial ﬁbrillary
acidic protein (GFAP) antibody and indirect immunocytochemistry.
Preparation of subcellular fractions and Western blotting
We obtained non-nuclear membranes and vesicular extracts from puriﬁed
astrocytes and different brain tissues (occipital lobe, hypothalamus and
posterior pituitary gland) as previously described (18). Preparations were
subjected to 15% SDS-PAGE, followed by transfer to nitrocellulose mem-
branes that were probed with antibodies against VGLUT-1 (rabbit polyclonal,
1 : 1000; provided by Dr R. H. Edwards, University of California, San
Francisco, CA, USA) (19), VGLUT-2 (rabbit polyclonal; 1 : 1000; Synaptic
Systems, Goettingen, Germany, cat no. 135102) or VGLUT-3 (guinea pig
polyclonal, 1 : 5000; Chemicon International, Temecula, CA, USA, cat No.
AB5421). Immunoreactivity of bands was detected using enhanced chemilu-
minescence (ECL; Amersham Biosciences Corp., Piscataway, NJ, USA). We
previously characterised the speciﬁcity of these VGLUT antibodies using their
respective antigens in adsorption controls (16).
Reverse transcriptase-polymersase chain reaction (RT-PCR)
Five adult (62 day-old) male rats were used to probe both the SON and SON
plus perinuclear zone for mRNA corresponding to all three VGLUT isoforms.
Total RNA was extracted using TRIzol
  Reagent (Invitrogen Corp.) and
protocols provided by the manufacturer as previously described (16). Total
RNA was used for reverse transcription using Oligo(dT)12)18 and super-
script
TM III reverse transcriptase (Invitrogen Corp.). Two pairs of primers
(each pair 35 cycles) for each of VGLUTs 1, 2 and 3 (GeneBank accession
numbers NM_053859, NM_053427 and NM_153725, respectively) were used
to amplify cDNA using PCR Core System I kit (Promega, Madison, WI,
USA). For VGLUT-1, in the ﬁrst round we used, forward 5¢-CCG GCA
GGA GGA GTT TCG AGG G-3¢ and reverse 5¢-AGG GAT CAA CAT
ATT TAG GGT GGA GGT AGC-3¢ primers (478 bp product). Ampliﬁed
Table 1. Antibody Dilutions and Sources.
Antibody Host Dilution Company or PI
Vesicular glutamate transporter type 1 Rabbit (r) 1 : 500 Synaptic Systems
Vesicular glutamate transporter type 1 Rabbit 1 : 1000 R.H. Edwards, UCSF
Vesicular glutamate transporter type 2 Rabbit 1 : 500 Synaptic Systems
Vesicular glutamate transporter type 2 Guinea Pig (gp) 1 : 2500 Chemicon
Vesicular glutamate transporter type 3 Guinea Pig 1 : 2000 Chemicon
Oxytocin-Neurophysin Mouse (m) 1 : 400 H. Gainer, NIH, PS38
Vasopressin-Neurophysin Mouse 1 : 400 H. Gainer, NIH, PS41
Neurophysin II (marker for VP neurones) Rabbit 1 : 500 Sigma
Neurophysin II Goat (g) 1 : 20 Santa Cruz Biotech
Glial ﬁbrillary acidic protein (marker for astrocytes) Mouse 1 : 500 Sigma
Glial ﬁbrillary acidic protein Goat 1 : 20 Santa Cruz Biotech
Neuroﬁlament (marker for neurones) Mouse 1 : 100 Calbiochem
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primers, forward 5¢-TAC TGG AGA AGC GGC AGG AAG G-3¢ and
reverse 5¢-CCA GAA AAA GGA GCC ATG TAT GAG G-3¢ (311 bp
product). For VGLUT-2 we used in the ﬁrst round, forward 5¢-AGC AAG
GTT GGC ATG TTG TCT G-3¢ and reverse 5¢-CGG TCC TTA TAG GAG
TAC GCG T-3¢ primers (698 bp product), while in the second round the
nested primers were forward 5¢-TGG TGC AAT GAC GAA GAA CAA G-3¢
and reverse 5¢-TCC TTT TTC TCC CAG CCG TT-3¢ (294 bp product). For
VGLUT-3, in the ﬁrst round the primers were forward 5¢-AGG AGT GAA
GAA TGC CGT GGG AGA T-3¢ and reverse 5¢-ACC CTC CAC CAG ACC
CTG CAA A-3¢ (535 bp product), while the second round nested primers were
forward 5¢-GAT GGG ACC AAC GAG GAG GGA GAT-3¢ and reverse
5¢-TGA AAT GAA GCC ACC GGG AAT TTG T-3¢ (322 bp product).
Results
VGLUT immunocytochemistry positive and negative control
experiments
Experiments testing the speciﬁcity of the VGLUT antibodies
used in this study have been published previously (16).
However, further experiments were performed to test their
speciﬁcity in the tissue under study. Expression of VGLUT-2
in the adult cerebellum has been described (20) as occurring in
the large mossy ﬁbre terminals in the granule cell layer and
along the thin climbing ﬁbres in the molecular layer. Immu-
noreactivity for VGLUT-1 occurs in the molecular layer,
labelling parallel ﬁbre terminals (Fig. 1A–D). In situ hybridi-
sation and protein expression experiments have shown
VGLUT-3 to be present in the hypothalamus and that its
protein expression is particularly high in the olfactory
tubercles (8, 21). Western blot experiments have bands with
molecular weights corresponding to the speciﬁc VGLUT
being immunoprobed (Fig. 1E). In addition to the nucleus of
the lateral olfactory tract (nLOT), strong VGLUT-3-ir can be
seen in the SON (Fig. 1F). Note that the punctate labelling in
the nLOT is diﬀerent than the cellular labelling observed in the
SON and is seen using the same antibody in the same section.
Negative control experiments, performed in the absence of
primary antibody exposure, were carried out in parallel with
all multilabelling immunocytochemical experiments. Further
control experiments, similar to those previously described
(16), in which the antibodies were preincubated with their
recognised peptide sequences were also performed. Both types
of negative control experiments resulted in the absence of
stained tissue.
VGLUT-3 in the SON
Cellular labelling for VGLUT-3 appeared throughout the
SON (Figs 1F and 2). Experiments using double-labelling for
VGLUT-3 and OT or VP resulted in apparent colocalisation
of peptide- and VGLUT-3-ir. Dorsal to the SON, scattered
cells of the anteriolateral hypothalamic area also displayed
VGLUT-3-ir (Fig. 2A). Additionally, lighter VGLUT-3 label-
ling was apparent in the ventral glial lamina and in cells of the
meninges. SON neuronal VGLUT-3-ir was clustered in the
perikarya, while labelling was absent in the nuclei of both
SON neurones and astrocytes, as determined by Hoechst
staining.
To determine if the VGLUT-3-ir was present intracellular-
ly, Z-series through SON sections immunoprobed for neuro-
physin II, GFAP, OT and VGLUT-3 were taken.
Extranuclear puncta representing VGLUT-3 are surrounded
by both the VP-speciﬁc peptide neurophysin II- (Fig. 2C) and
GFAP-ir (Fig. 2D). Shown in all three dimensions in Fig. 2(D,
insets 1–3) VGLUT-3-ir is localised within the boundaries of
GFAP-ir, suggesting SON astrocytes express this transporter.
OT-positive cells were also seen to contain VGLUT-3-ir
(Fig. 2E–G). Interestingly, many of the magnocellular neu-
rones that are most immunoreactive for VGLUT-3 displayed
2 or 3 nucleoli and regions of ribosome synthesis (Fig. 2C,
insets).
The VGLUT-3-ir did not appear to extend into the
dendrites or along axons. Rather, it was limited to the
perikarya. VGLUT-3-ir was also seen in astrocytic somata
but not processes. Strong labelling was also apparent in the
endothelial and meningeal cells at the base of the brain.
There, the labelling appears more distributed and not
necessarily restricted to perinuclear areas.
VGLUT-2 in the SON
Two polyclonal antibodies to VGLUT-2 were used to localise
the protein. Punctate labelling by both guinea pig and rabbit
antibodies can be seen throughout the SON and was also
particularly strong dorsal to the nucleus. Multilabelling
experiments, including probing for the VP cell marker neuro-
physinII,revealedcolocalisationofVGLUT-2-irwithmanyof
the neurophysin II-positive cell processes (Figs 3 and 4).
Examples of neurophysin II-positive dendrites and somata
containingintracellularVGLUT-2-irareshowninFig. 3(A–E).
Because these cells are contacted by many glutamatergic
terminals, it was necessary to perform Z-series acquisitions to
besuretheVGLUTimmunoreactivitywasoccurringwithinthe
boundaries of speciﬁc magnocellular neurones as judged by
their peptide immunoreactivity. Additionally, strong punctate
labelling, appearingjustoutsidemuchoftheneurophysinII-ir,
morphologically reveals putative glutamatergic synapses onto
these cells (Fig. 3A,C,E).
Similar multilabelling experiments were performed to
investigate VGLUT-2 and OT colocalisation. OT-positive
cells also appeared to receive glutamatergic input from
VGLUT-2 immunoreactive terminals (Fig. 5D, arrows).
Intracellular VGLUT-2-ir was apparent in several OT-posit-
ive dendrites (Fig. 5). Unlike VGLUT-3-ir, colocalisation of
VGLUT-2 with GFAP within the VGL was not evident.
Furthermore, meningeal and endothelial cells did not show
detectable levels of VGLUT-2-ir with either VGLUT-2
antibody.
OT and VP neurones of the SON can express VGLUT-2
or VGLUT-3. However, the question remained as to
whether or not an individual magnocellular neurone could
express both VGLUTs. Multilabelling for the two peptide
hormones along with the two VGLUTs revealed VGLUT-2-
and VGLUT-3-ir in both types of magnocellular neurones
(Fig. 6). Although strong VGLUT-3-ir appeared in virtually
all labelled neurones (Figs 2, 6 and 7), this was not the case
for VGLUT-2. Some magnocellular neurones were clearly
more immunoreactive than others for VGLUT-2 (Fig. 6D,
inset), suggesting that VGLUT expression may be a regu-
lated phenomenon.
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Just lateral to the SON, strong VGLUT-1-ir was visible
(Figs 4A,C and 7). Although distribution of VGLUT-1
staining was noticeable within the SON, it was much less
pronounced than that of VGLUT-2. VGLUT-1 labelling
was slightly stronger in the dendritic zone and was
completely absent in the optic chiasm. Similar to the
pattern seen with the VGLUT-2 antibodies, little or no
VGLUT-1-ir was present in the VGL, in the astrocytes
therein, along the meninges or along blood vessels (Fig. 7).
Colocalisation experiments revealed the presence of
VGLUT-1 outside the VGLUT-3 positive OT- or VP-
labelled SON neurones (Fig. 7). This is consistent with
VGLUT-1 residing mainly within glutamatergic terminals
in the SON.
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Fig. 1. Antibody control experiments. (A–D) The cerebellum shows a stereotypic labelling pattern for vesicular glutamate transporter (VGLUT)-1 and for both
VGLUT-2 antibodies. (B,D) Expansions of the areas shown in (A)a n d( C). (B1) VGLUT-2 labels the granule cell synapses in the granule layer (GL) in addition
to the climbing ﬁbres (cf) coursing toward Purkinje cells (pc) in the molecular layer (ML). (D) Demonstration of VGLUT-2 immunoreactivity similar to as seen
in (B) using a diﬀerent VGLUT-2 antibody. (E) Western blots using the same antibodies in addition to the VGLUT-3 antibody used for immunocytochemistry
in (F). (F) VGLUT-3 is present in the nucleus of the lateral olfactory tract. Strong immunoreactivity is also seen in the SON. OL, Occipital lobe; H,
h y p o t h a l a m u s ;A s P ,a s t r o c y t ec u l t u r e ;P P ,p i t u i t a r y ;r ,r a b b i t ;m ,m o u s e ;g u i n e ap i g ;g p .
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Fig. 2. Vesicular glutamate transporter (VGLUT)-3 expression by neurones, astrocytes, and their underlying meningeal cells. (A) Neurophysin positive cells of
the supraoptic nucleus (SON) are immunoreactive for VGLUT-3. Scattered cells of the lateral hypothalamic area also show VGLUT-3-immunoreactivity (ir)
(arrows). (B) GFAP-ir of the VGL separates the SON from VGLUT-3 immunoreactive meninges and endothelial cells at the base of the brain (arrows). (C)
VGLUT-3 is located in the interior of SON neurones immunoprobed with neurophysin II. Several SON neurones with strong VGLUT-3 labelling also have
multiple nucleoli (* and expanded in insets C1a n dC2, arrows indicate nucleoli). The scale bar in (C) also applies also to (D). (D) Astrocytes of the VGL express
VGLUT-3 (open arrows). (D1–D3) Expanded X–Y, Y–Z and X–Z projections at the crosshair point inside the red square in (D) show that astrocytic VGLUT-
3-ir is completely surrounded by GFAP-ir. Z-thickness is 20 lmi n( C)a n d( D). (E–G) Colocalisation of VGLUT-3 (E,G) with oxytocin (OT) (F,G). Open arrows
in (E)a n d( G) identify several oxytocin-positive cells colocalised with VGLUT-3 immunoreactive puncta. The scale bar in (E)a l s oa p p l i e st o( F)a n d( G). OC,
Optic chiasm; BV, blood vessel.
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To corroborate the immunocytochemical experiments, we
performed RT-PCR using mRNA isolated from SON and
SON plus the perinuclear zone of ﬁve adult rats, the latter
serving as a positive control for all three VGLUTs (Fig. 8,
top). Whereas PCR products for VGLUTs-2 and -3 were
found in all ﬁve of the isolated SONs, PCR products for
VGLUT-1 were found in only three of ﬁve cases (Fig. 8,
bottom). Consistent with the immunocytochemical results,
PCR products representing the mRNA for all three VGLUT
isoforms were found in SON plus perinuclear zone from all
ﬁve rats. These results agree with the idea that VGLUTs 2
and 3 are heavily expressed in the SON, whereas VGLUT-1
is only sparsely expressed. Additionally, these results are
also consistent with the known presence of mRNAs in
terminals.
Discussion
For several years, glutamate has been known to be the main
excitatory transmitter involved in neuroendocrine regulation
(22, 23). In addition to general excitation, glutamate-impli-
cated phenomena occurring in the magnocellular neuroendo-
crine system include osmoresponsiveness (24, 25) and
bursting rhythmogenesis (26). Here, we present evidence that
an additional source for that glutamate may be somatoden-
dritically released glutamate from magnocellular neurones
themselves.
A precendent already exists for intranuclear release of
substances from magnocellular neurones. The release of OT
and VP from SON neuronal somata and dendrites under
different conditions can inﬂuence presynaptic activity (1, 27).
The presence of glutamate-containing MVs in magnocellular
neuronal terminals in the NL has also been described (3). The
(A)
(B)
(C)
(D) (E)
Expanded
OC
80 µm
40 µm
D
E
A
X-Z projection
B
C
Y
-
Z
 
p
r
o
j
e
c
t
i
o
n VGLUT-2 r
NP-II   g
Hoechst
Fig. 3. Vasopressinergic magnocellular neurone expression of vesicular glutamate transporter (VGLUT)-2-ir. Upper-left inset: area of supraoptic
nucleus expanded in the ﬁgure. Further expansions of outlined areas (A–E) are shown in panels on right. The X–Z and Y–Z projections of neurophysin
II-immunoreactivity (ir) completely surrounding that for VGLUT-2 can be seen at the points of the crosshairs (Z-thickness is 12 lm). Expansions of internally
localised VGLUT-2-ir found at one such point can be seen on the right (circled in A–C). Putative aﬀerent synapses represented by large VGLUT-2 puncta are
adjacent to the peptide-labelled cells (arrows in A,C,E). OC, Optic chiasm.
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SON and, more relevant here, in magnocellular somata and
dendrites (15, 28). This glutamate was postulated to serve
mainly a metabolic function and the possibility for somato-
dendritic exocytosis of glutamate largely remained uninvesti-
gated. In the present study, we oﬀer strong evidence that the
somatodendritic compartment of SON neurones contains the
principle machinery that deﬁnes a glutamatergic phenotype.
ThisisconsistentwiththereportedpresenceofVGLUT-2-irin
the NL (4). Although earlier investigations of VGLUTs have
described a complementary expression pattern of the proteins,
we present evidence for both VGLUT-3 and VGLUT-2
expression by OT- or VP-positive SON neurones. The possi-
bility of multiple VGLUTs in a given neurone presents some
obvious and interesting questions regarding the speciﬁc roles
for the diﬀerent VGLUTs found within the same neurone.
Potential functions of VGLUT-3 in the SON
Cloned and described by three independent groups in 2002,
VGLUT-3 was shown to exist in serotonergic, cholinergic,
andGABAergicneurones(8,9,21).UnlikeVGLUTs-1and-2,
VGLUT-3-ir has been found in somata and dendrites in
addition to synaptic terminals. Here, we report the presence
of VGLUT-3 in the somata of magnocellular neurones,
astrocytes, along the endothelium and along meningeal cells.
One commonality shared by these various cell types in this
particular region is a high level of metabolic activity.
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Fig. 4. (A–C) Colocalisation of vesicular glutamate transporter (VGLUT)-2- and peptide hormone-immunoreactivity can be seen with a diﬀerent VGLUT-2
antibody (arrows). Colocalisation occurs in somata and dendrites of magnocellular neurones. OT, Oxytocin; NP-II, neurophysin II.
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interneurones, SON cells are especially active. In the resting,
nonactivated state (e.g. hydrated animal), OT and VP cells
continue to discharge action potentials spontaneously both
in vivo and in vitro, resulting in basal circulating concentra-
tions of these hormones. Under these conditions, the cells
continue to synthesise the peptide hormones and electron
micrographs display magnocellular neurones densely popu-
lated with peptide-containing DCVs.
When presented with a physiological challenge (e.g. dehy-
dration or lactation/suckling), magnocellular neurones of the
SON and PVN become highly activated. A number of plastic
anatomical and electrophysiological changes occur through-
out the nucleus. Some examples include: (i) the size of
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Fig. 5. Oxytocin (OT)-immunoreactive dendrites show strong labelling for vesicular glutamate transporter (VGLUT)-2. Upper-left inset: area of supraoptic
nucleus expanded in the ﬁgure. Projections in the X–Y, X–Z, and Y–Z planes from the points of the crosshairs show OT-ir completely surrounding that for
V G L U T - 2( Z - t h i c k n e s si s1 2¼ m). Expansions of internally localised VGLUT-2 at one such point can be seen below (circled in A–C). VGLUT-2 labelling was
not as apparent in OT-positive somata. Large puncta (arrows in D) indicate putative aﬀerent glutamatergic synapses onto an OT-immunoreactive process. OC,
Optic chiasm.
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OT cells bursting synchronously and the VP cells exhibiting a
stereotypic phasic ﬁring pattern (30); and (iii) astrocytic
processes in the neural lobe and SON retracting, allowing for
increases in neurone-neurone appositions and synapse for-
mation (31). With these changes, elevated levels of circulating
hormones ensue.
The blood supply to the SON is also distinctive. Along with
thePVN,theSONisenrichedwiththehighestcapillarydensity
in the brain, at least twice as high as observed in other brain
nuclei (32). Doubtless, the cells of this especially active and
plastic nucleus require extraordinary levels of factors garnered
from an enriched blood supply and additionally need a readily
accessible pool of glutamate to maintain their high metabolic
(A)
(B)
(C)
(D)
14 µm
VGLUT-3 gp
VGLUT-2 r
OT m
NP II  g
Fig. 6. Colocalisation of vesicular glutamate transporter (VGLUT)-2 and 3 in magnocellular supraoptic nucleus (SON) neurones. (A) VGLUT-2- and
3-immunoreactivity appears in the perikarya of SON cells. Dashed lines in A and B approximate cell boundaries. (B) Oxytocin (OT)- and neurophysin II (NP-
II)-ir reveals a heterogeneous population of peptidergic neurones in this section. (C) An OT-positive cell is positive for bo t hV G L U T - 2a n d- 3( a r r o w h e a d ) .I n
the same ﬁeld, a VGLUT-3-positive, although only faintly VGLUT-2-positive cell is indicated (asterisk). A few large puncta representing the clustering of
numerous VGLUT-2 positive vesicles forming a putative glutamatergic synapses are indicated (arrows in C and D). (D) Neurophysin-II-positive cells were
immunoreactive to both VGLUTs (arrowhead and inset).
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involvement in exocytosis, the presence of VGLUT-3-ir in this
case possibly suggests a metabolic function similar to that
proposedbyMeekeret al.(15).Consistentwiththishypothesis
is the strong VGLUT-3-ir observed in neurones with multiple
nucleoli (Fig. 2C).
(A)
(B)
(C)
(D)
(E)
A.1 D.1
C.1
SON
A.1 C.1 D.1
100 µm
VGLUT-1 r
VGLUT-3 gp
OT+VP m
Hoechst
Fig. 7. Vesicular glutamate transporter (VGLUT)-1 expression in the supraoptic nucleus (SON). (A–C) Though faint labelling is seen inside the SON proper,
strong VGLUT-1-immunoreactivity consistent with a terminal distribution occurs in the cell sparse region lateral to the nucleus (arrows in A and C).
(D) Colocalisation of oxytocin and vasopressin with VGLUT-3 but not VGLUT-1 is seen. (A1,B1,C1) Expansions from boxes in the respective panels. (E)i st h e
same as (D1) with the addition of the nuclear stain Hoechst.
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VGLUT-2 expression is strongly linked to glutamatergic
transmission. It is known to exist at many well-characterised
glutamatergic synapses and is restricted to sites of known
release. VGLUT-2-ir in OT and VP neurones is in agreement
with a previous study demonstrating VGLUT-2 mRNA in
the magnocellular hypothalamic nuclei (10). However,
mRNA expression is not an infallible indication of protein
expression and such studies reveal no information regarding
the speciﬁc location of the molecules of interest. Here, we add
to that work by demonstrating that VGLUT-2-ir is not only
expressed in local glutamatergic neurones and terminals
contacting SON neurones, but also in OT/VP-positive SON
neurones themselves. Colocalisation of the transporter within
the magnocellular neurones is now established, suggesting
that these cells may release both glutamate and either OT or
VP from their somata and dendrites.
The suggestion of dendritic glutamate release from mag-
nocellular neurones presents an interesting puzzle concerning
its function. The clustering of microvesicles in SON magno-
cellular dendrites or somata has not been described, suggest-
ing that glutamate is probably not released at speciﬁc sites in
high concentration (i.e. synapses), but is instead released from
a more general area (i.e. a somatic or dendritic zone). Because
these cells and many of their afferent terminals express
glutamate receptors, the released glutamate may function in
autocrine, paracrine or retrograde transmission and, in some
cases, perhaps contribute to a feed-forward activation system.
A similar autocrine feed-forward system exists for OT acting
on OT neurones during the episodic ﬁring of milk ejection
bursts. There, somatodendritic released OT results in
enhanced local concentrations of OT which lead to an
increased frequency and amplitude of subsequent milk
ejection bursts (33–35). Furthermore, autocrine signalling of
VP-cell derived dynorphin has been shown to aﬀect VP
neurone bursting (36, 37).
Whereas activation of pre- or post-synaptic ionotropic
glutamate receptors would result in direct membrane depo-
larisation and/or release of presynaptic transmitter, the
activation of pre- and post synaptic metabotropic glutamate
receptors (mGluRs) results in more subtle forms of modula-
tion. Evidence exists for the presence of mGluRs on magno-
cellular neurones, and on glutamatergic and GABAergic
terminals in the SON (38, 39). Activation of terminally
located group III mGluRs causes a reduction in the frequency
of spontaneous glutamatergic and GABAergic release. Alter-
natively, activation of postsynaptic group I mGluRs induces
excitation through activation of inward currents carried by
K
+ or Ca
2+ (38, 39). Therefore, the qualitative result of
somatodendritic released glutamate will depend upon which
receptors are subsequently activated.
Consistent with the immunocytochemical evidence pre-
sented in a recent study, VGLUT-2 is also probably
involved in afferent glutamatergic transmission in the SON
(40). Larger VGLUT-2 immunoreactive puncta are seen
along dendrites and somata of SON neurones, which may
represent glutamatergic terminals forming synapses within
the nucleus.
VGLUT-1 immunoreactive input to the SON
Although VGLUT-1-ir in the SON was not as intense as that
seen for either VGLUT-2 or VGLUT-3, strong labelling was
evident lateral to the nucleus. This area is enriched with mitral
cell axons and terminals that form the glutamatergic lateral
olfactory tract (41–43). Mitral cell and glomerular layers of
the olfactory bulb are immunopositive for VGLUT-1 (40).
SON + perinuclear zone
VGLUT-1
OC
SON
(S + P)
(S + P) SON
VGLUT-2
(S + P) SON
VGLUT-3
(S + P) SON
5/5 3/5 5/5 5/5 5/5 5/5 Frequency
M
400 bp
300 bp
200 bp
80 µm
(a)
Fig. 8. Detection of vesicular glutamate transporter (VGLUT) mRNA in the supraoptic nucleus (SON). Top: Micrograph showing from where the tissue was
collected, either the SON only (n ¼ 5) or the SON + perinuclear zone (S + P, n ¼ 5). OC, Optic chiasm. Bottom: Reverse transcriptase-polymerase chain
reaction analysis from SON and S + P tissue reveals the presence of mRNA for all three VGLUT isoforms: VGLUT-1(311 bp), VGLUT-2(294 bp) and
VGLUT-3(322 bp). M, DNA ladder marker. Detection frequencies for the mRNAs are given at the bottom.
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glomerular layer, this oﬀers the possibility of VGLUT-1 being
the transporter used by this cell type.
The detection of VGLUT-1 mRNA-containing SON tissue
in three of ﬁve cases along with ﬁve of ﬁve cases using SON
tissue plus the surrounding perinuclear region is consistent
with a previous report showing only faint labelling for
VGLUT-1 mRNA in the SON and perinuclear area (11).
However, neither our study nor theirs addresses the precise
localisation of VGLUT-1 mRNA within speciﬁc cell types of
the perinuclear zone. A recent anatomical study addressed the
possibility of glutamatergic perinuclear neurones by exploring
the origin of aﬀerent glutamatergic terminals in the SON (13).
These results, together with a previous physiological study
(44), suggest that many perinuclear neurones are indeed
glutamatergic.
Is Dale’s principle upheld?
Magnocellular neurones have two well-documented peptide
release sites: (i) the NL terminals and (ii) somatodendritically
within nuclei. However, somatodendritic release of peptides
does not necessarily mirror peripheral release (1). Little is
known concerning MV exocytosis in the NL or from the
dendrites. The intranuclear colocalisation of VGLUT-2 with
OT and VP agrees with evidence ﬁrst oﬀered in a recent
review showing that the neural lobe was immunoreactive for
VGLUT-2 (4). In agreement with Dale’s principle (45), this
suggests that the somata and dendrites, similar to the
terminals, release the same transmitters: peptides and glu-
tamate. However, the assumption that the VGLUT-2 label-
ling seen in the NL is in magnocellular terminals may not be a
safe one. First, it has long been known that there are
terminals in the NL originating from neurones other than
magnocellular neurones (46). Second, neocortical astrocytes,
and thus possibly those in the NL (pituicytes), can express
VGLUT-2 (16). In the absence of a positive magnocellular
terminal marker, it remains unclear which cell type in the NL
(pituicyte, OT, VP, non-neurosecretory neurone, endothelial,
etc.) expresses VGLUT-2.
Furthermore, ultrastructural experiments are still lacking
investigating the subcellular localisation of speciﬁc VGLUT
isoforms to particular classes of somatic and dendritic MVs.
Information addressing these issues could shed further light
on alternative functions of VGLUTs and better clarify
whether SON neurones express VGLUT-1 at levels not
detectible at the light microscopic level. Additionally, phy-
siological experiments monitoring VGLUT expression and
somatodendritic release of glutamate under different condi-
tions could address whether or not triggers for glutamate
release are distinctive or the same as those for peptide release.
Summary
In the present study, we investigate the presence of VGLUT-1,
2 and 3 protein in the SON. Immunoreactivity for VGLUT-1
was observed mainly lateral to the SON, whereas VGLUT-2-ir
was apparent in positively identiﬁed magnocellular neuronal
somata and dendrites. Expression of VGLUT-3 was seen in
SON neurones as well as local SON astrocytes, in addition to
being along endothelial and meningeal cells. Magnocellular
neuronal expression of VGLUT-3 was mainly restricted to the
perinuclear area of the soma. From these data, we suggest that
magnocellular SON neurones are both peptidergic and gluta-
matergic.
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